62141-22-4

Usage

InChI:InChI=1/C10H18O3/c1-2-13-10(12)7-8-3-5-9(11)6-4-8/h8-9,11H,2-7H2,1H3

Upstream product

• 5452-75-5 ethyl 2-cyclohexylacetate 
• 58012-34-3 ethyl 4-oxocyclohexaneacetate 
• 62141-26-8 ethyl 1,4-dioxaspiro[4.5]dec-8-ylacetate 
• 51656-91-8 ethyl 1,4-dioxaspiro[4,5]dec-8-ylideneacetate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 
• 7440-02-0 nickel 

Downstream Products

• 1350476-36-6 ethyl [4-({[(1Z)-2-tert-butyI-2-methyl-1-oxido-1λ5-diazan-1-ylidene]amino}oxy)cyclohexyl]acetate 
• 1350476-35-5 [4-({[(1Z)-2-tert-butyI-2-methyl-1-oxido-1λ5-diazan-1-ylidene]amino}oxy)cyclohexyl]acetic acid 
• 1350434-23-9 ethyl [4-({[4-(trifluoromethyl)phenyl]sulfonyl}oxy)cyclohexyl]acetate 
• 1438249-89-8 ethyl 2-(4-(5-bromopyridin-2-yloxy)cyclohexyl)acetate 
• 1438250-79-3 ethyl 2-(4-(5-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-2,3'-bipyridin-6'-yloxy)cyclohexyl)acetate 
• 1438249-90-1 ethyl 2-(4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yloxy)cyclohexyl)acetate 
• 58012-34-3 ethyl 4-oxocyclohexaneacetate 
• 53631-80-4 ethyl 2-(cyclohex-3-en-1-yl)acetate 
• 116941-11-8 2-(4-hydroxycyclohexyl)acetamide 

Relevant academic research and scientific papers

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

Complementary and selective oxidation of hydrocarbon derivatives by two cytochrome P450 enzymes of the same family

The cytochrome P450 enzymes CYP101B1 and CYP101C1, which are from the bacterium Novosphingobium aromaticivorans DSM12444, can hydroxylate norisoprenoids with high activity and selectivity. With the goal of expanding and establishing their substrate range with a view to developing applications, the oxidation of a selection of cyclic alkanes, ketones and alcohols was investigated. Cycloalkanes were oxidised, but both enzymes displayed moderate binding affinity and low levels of productive activity. We improved the binding and activity of these substrates with CYP101B1 by making the active site more hydrophobic by switching a histidine residue to a phenylalanine (H85F). The presence of a ketone moiety in the cycloalkane skeleton significantly improved the oxidation activity with both enzymes. CYP101C1 preferably catalysed the oxidation of cycloalkanones at the C-2 position whereas CYP101B1 oxidised these substrates with higher productivity and at positions remote from the carbonyl group. This demonstrates that the binding orientation of the cyclic ketones in the active site of each enzyme must be different. Linear ketones were also oxidised by both enzymes but with lower activity and selectivity. Cyclic substrates with an ester directing group were more efficiently oxidised by CYP101B1 than CYP101C1. Both enzymes catalysed oxidation of these esters with high regioselectively on the ring system remote from the ester directing group. CYP101C1 selectively oxidised certain terpenoid ester substrates, such as α-terpinyl and citronellyl acetate more effectively than CYP101B1. Overall, we establish that the high selectivity and activity of these enzymes could provide new biocatalytic routes to important fine chemicals.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

IMMUNOREGULATORY AGENTS

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases,

DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES

A compound having the structure (I) or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen, deuterium, —OH, —OC1-6alkyl, or halogen; R8 is hydrogen, deuterium, or C1-6alkyl; R11 and R12 are independently hydrogen, —C1-6alkyl, —OH, —OC1-6alkyl, or halogen; R13 and R14 are independently —C1-6alkyl, —(CH2)1-2OH, or —OC1-6alkyl, or, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclic ring containing one nitrogen atom and 0 or 1 oxygen atoms, wherein said ring is unsubstituted or mono-, di- or tri-substituted with halogen or —C1-6alkyl; R15 is (CR1R2)nC(O)OR16, wherein n is 0, 1 or 2, —C(O)NHCH(R17)OR16, or —C(O)NHCH(R17)C(O)NHCH(R18)C(O)OR16; R16 is hydrogen, C1-6alkyl, or (CH2)1-2N+R19R20R21; R1, R2, R4, R5, R6, R7, R9, R10, R17, R18, R19, R20, and R21 are independently hydrogen or —C1-6alkyl; and stereoisomers thereof, and pharmaceutically acceptable salts thereof, and pharmaceutically acceptable salts of stereoisomers thereof

Synthesis and evaluation of [(1R)-1-amino-2-(2,5-difluorophenyl)ethyl] cyclohexanes and 4-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]piperidines as DPP-4 inhibitors

A series of 4-amino cyclohexanes and 4-substituted piperidines were prepared and evaluated for inhibition of DPP-4. Analog 20q displayed both good DPP-4 potency and selectivity against other proteases, while derivative 20k displayed long half life and mod

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11Beta-HSD type 1 activity. X-17377

BENZOTHIENO’2,3-D! PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES

This invention relates to novel compounds of formula (I) and processes for their preparation, their use for of treating diseases, particularly hyperproliferative diseases such as cancer, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly hyperproliferative diseases such as cancer. Wherein m is 0, 1 or 2; R3 is *-O(CH2)n AR, wherein Ar is phenyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl od pyridazinyl, wherein Ar can optionally be substituted.

NEW DERIVATIVES OF PYRIDIL PIPERAZINE OR PYRIDAZINYL PIPERAZYL, PROCESS FOR PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THESE COMPOUNDS

Compounds of formula I in which R1 denotes hydrogen, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, an optionally substituted monocyclic or bicyclic aryl, an optionally substituted hetaryl, an optionally substituted arylalkyl or one of the groups —OR2, —NR3R4, W denotes nitrogen or X, Z independently of one another denote nitrogen or CH and in the case that W denotes a nitrogen atom, X must be the group, A denotes a valency dash or a carbonyl group, B denotes a valency dash or a C1-C6 alkylene chain optionally substituted once or several times by lower alkyl or an OR2 group, D denotes a valency dash and, in the case that X is a nitrogen atom, can also be a carbonyl group in which case A, B and D may not simultaneously denote a valency dash, R2 denotes hydrogen, lower alkyl or arylalkyl, R3 and R4 independently of one another denote hydrogen or lower alkyl or together with the nitrogen atom to which they are bound form a five to six-membered heterocyclic ring, R5 denotes hydrogen or a group OR2, processes for the production thereof as well as pharmaceutical agents containing these compounds for the treatment of diseases which are the result of thrombo-embolic events.